Nouscom bolsters its leadership team with the appointments of Sven Gogov, MD, as Chief Medical Officer and Maria Arce-Tomas, PhD, as Vice President, Head of Regulatory Affairs

0

BASEL, Switzerland, September 9, 2022 /PRNewswire/ — Nouscom, a clinical-stage immuno-oncology company developing ready-to-use and personalized viral-vectored immunotherapies, today announced the promotion of Sven GogovMD, to the Chief Medical Officer (CMO) and the appointment of Maria Arce-Tomas, PhD, as Vice President, Head of Regulatory Affairs. Dr. Gogov will join the management team and be responsible for the development of the company’s portfolio of clinical projects.

We are happy to welcome Sven to our management team. Sven joined Nouscom in October last year as part of our clinical development expansion and has been instrumental in leading the clinical development strategy for our viral vector immunotherapies. He is an exceptional clinical leader with deep expertise in targeted therapeutic research and oncology, acquired through his successful career in drug development.“, said Marina Udier, CEO of Nouscom. “I am also delighted to welcome Maria as the new Vice President, Head of Regulatory Affairs. Maria has extensive experience in global regulatory affairs in the pharmaceutical industry and her and Sven’s expertise will be essential in advancing our clinical programs and initiating phase 2 studies on NOUS-209.

“Dr. Gogov succeeds Dr. Patricia Delaite who is looking for a new opportunity outside of Nouscom,Marina Udier added. “Patricia has been an important collaborator at Nouscom, playing an instrumental role in the Phase 1 studies of NOUS-209 and NOUS-PEV. We thank Patricia for her impactful contributions and wish her well in her future endeavours..”

dr. Sven Gogovchief medical officer at Nouscom, said: The company has made significant progress advancing its lead candidates NOUS-209 and NOUS-PEV with the potential to transform the treatment of patients with hard-to-treat solid tumors. It’s been great working with the team since I joined the company in October and I look forward to leading the planned Phase 2 clinical development for NOUS-209, which has shown exciting and promising data in previous studies.1.”

Sven GogovMD

Sven Gogov, MD, is an experienced global clinical development leader who brings over 15 years of experience in pharmaceutical oncology and regulatory interactions to Nouscom. Sven joined Nouscom in October 2021 as Vice President of Clinical Development at Incyte where he served as Executive Director, Global Immuno-Oncology, responsible for clinical strategy development and trial execution for multiple actives targeting the tumor microenvironment.

Prior to Incyte, Sven held senior clinical development positions in oncology at Novartis and OSI Pharmaceuticals, conducting first human and registration studies for several successful filings in Europe, US, Switzerland and Asia.

Sven began his career in the pharmaceutical industry at AstraZeneca as a clinical research physician, previously holding an academic position in the Department of Medicine and Medical Oncology, University Health Network at Toronto, Canada.

Maria Arce-TomasPhD, BPharm

Maria Arce-Tomas brings to Nouscom extensive experience in global regulatory affairs having held executive positions in various pharmaceutical and biotechnology companies, including Novo Nordisk, GE Healthcare, Takeda, Abbott, Norgine and GSK.

Maria joins Nouscom from PharmaMar where she was Global Head of Regulatory Affairs, responsible for the entire PharmaMar Group product portfolio.

Maria has been recognized for raising the standards of leadership, regulatory science, and achieving key business goals for key assets of large and small biotech companies.

Maria holds a Bachelor of Pharmacy and a Master of Science in Toxicology from the University of Valence in addition to a doctorate in biochemistry from King’s College London.

References

1. Presentation of ASCO: First Clinical and Immunogenicity Results Including All Subjects Enrolled in a Phase I Study of NOUS-209, a Ready-to-Use Immunotherapy with Pembrolizumab for the Treatment of Tumors with Mismatch Repair Deficiency/Global Instability microsatellites (dMMR), Professor Marwan G. FakihMD

About Uscom

Nouscom is a clinical-stage immuno-oncology company developing next-generation, ready-to-use, personalized cancer vaccines. Nouscom’s proprietary technology platform harnesses the full power of the immune response by combining viral vector vaccines based on multiple neoantigens with other immunomodulators.

Nouscom is currently advancing the clinical development of its wholly owned programs:

  • NOUS-209 (lead), a ready-to-use cancer immunotherapy for the treatment of MSI-H solid tumors, and
  • US-PEV, a personalized vaccine for the treatment of advanced melanoma or lung cancer

Nouscom also exclusively licensed VAC85135, a ready-to-use cancer vaccine that received IND clearance from the US FDA, developed under a multi-project partnership agreement.

Nouscom is led by an experienced management team with deep roots in the pharmaceutical and biotechnology industry and is a veteran in the field of viral vector vaccines.

Nouscom, which was founded in 2015 and is headquartered in Basel, Switzerland with operations in Roma, Italyis backed by international life science investors.

For more information about Nouscom, please visit the Company’s website at www.nouscom.com or follow us on LinkedIn

contacts:

Wecom
Rick Davischief operating officer
E : [email protected]
T: +41 61 201 1835

MEDISTRAV Consulting
Sylvie BerrebiEleanor Perkin
E : [email protected]
T: +44 (0) 203 928 6900

SOURCEWecom

Share.

Comments are closed.